GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Probability of Financial Distress (%)

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Probability of Financial Distress (%) : 0.02% (As of Jul. 10, 2025)


View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%) is 0.02%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%)

For the Drug Manufacturers - General subindustry, Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%) falls into.


;
;

Jiangsu Hengrui Pharmaceuticals Co Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-8.59

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=0.02%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Jiangsu Hengrui Pharmaceuticals Co Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Hengrui Pharmaceuticals Co Business Description

Traded in Other Exchanges
Address
No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
Executives
Zhang Lian Shan Directors, senior managers
Sun Xu Gen senior management
Yuan Kai Hong senior management
Zou Jian Jun senior management
senior management
Zhang Yue Hong senior management
Liu Xiao Han senior management
Zhou Yun Shu Directors, senior managers
Liao Cheng senior management
Wang Hong Sen senior management
Zhou Song senior management
Tao Wei Kang senior management
Jiang Su Mei senior management
Dai Hong Bin Directors, senior managers
Sun Jie Ping Directors, senior managers

Jiangsu Hengrui Pharmaceuticals Co Headlines

No Headlines